During the third quarter of 2017, we revised the June 2016 Plan.
Generally, these RSUs vest over a three-year period.
Amortization expense was approximately $46 for both the three months ended September 30, 2018 and September 30, 2017, respectively, and approximately $139 for both the nine months ended September 30, 2018 and September 30, 2017, respectively.
Our effective income tax rate was 29.7% and 30.0% in the first nine months of 2018 and 2017, respectively.
Our effective income tax rate was 28.9% and 31.1% in the third quarters of 2018 and 2017, respectively.
In June 2016, we announced plans to restructure operations by phasing out production at our Elkhart facility by the end of 2018 and transitioning it into a research and development center supporting our global operations ("June 2016 Plan").
During the three and nine months ended September 30, 2018, we recognized a decrease of revenues of $18 and an increase of $68, respectively, that were included in contract liabilities at the beginning of the period.
The decrease in the effective tax rate for the nine months ended September 30, 2018, compared with the same period in 2017, was primarily attributed to the previously mentioned statutory tax rate reduction resulting from the Tax Act.
for the nine-month periods ended September 30, 2018 and 2017, since the revenue target was not deemed likely to be attained based on our current forecast.
Transaction losses for the three and nine months ended September 30, 2018 were $1,740 and $2,658, respectively and transaction gains for the three and nine months ended September 30, 2017 were $960 and $2,517, respectively, which have been included in other income (expense) in the Condensed Consolidated Statement of Earnings.Gross margin as a percent of sales was 35.4% in the third quarter of 2018 compared to 35.3% in the third quarter of 2017.
Research and development expenses were $6,517 or 5.5% of sales in the third quarter of 2018 compared to $6,380 or 6.0% of sales in the comparable quarter of 2017.
Gross margin as a percent of sales was 34.9% in the nine months of 2018 compared to 34.5% in the first nine months of 2017.
Sales were $118,859 in the third quarter of 2018, an increase of $12,616 or 11.9% from the third quarter of 2017.
Research and development expenses were $19,500 or 5.6% of sales in the nine months ended September 30, 2018 compared to $18,432 or 5.9% of sales in the comparable prior year period.
The Noliac acquisition, which was completed in May 2017, added $6,952 in sales in the nine months of 2018 and $4,097 in the first nine months of 2017.
Operating earnings were $16,118 or 13.6% of sales in the third quarter of 2018 compared to operating earnings of $13,111 or 12.3% of sales in the comparable quarter of 2017.
Other sales increased $6,003 or 15.9%.